Headlines

AbbVie Inc. (ABBV) Q4 2025 (USD): Adj. EPS 2.71 (exp. 2.65), Revenue 16.6bln (exp. 16.41bln); Q4 results include unfavourable impact of 0.71/SHR related to acquired IPR&D and milestones expense

Newsquawk Staff ·

Drug Breakdown

  • Skyrizi 5.01bln
  • Rinvoq 2.37bln (exp. 2.41bln)
  • Humira 1.25bln

Guidance

  • FY26 adj. EPS view 14.37-14.57 (exp. 14.22).

What it means

AbbVie reported Q4 earnings that topped expectations for both adjusted EPS and revenue, indicating stronger operational performance. However, the unfavorable impact related to acquired in-process R&D and milestones may raise some concerns about future expenses. This result could bolster sentiment in the biotech sector, yet investors should watch the guidance closely, as it suggests further stability even amidst product-specific challenges.

Related headlines